GTF2IP4

Across TCGA pan-cancer cohorts, GTF2IP4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GTF2IP4 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher GTF2IP4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GTF2IP4 expression acts as an unfavorable survival marker.

ACC, UCEC, and LIHC are the cancer types where GTF2IP4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
UCEC	OS	Median	III,IV	0.061	0.588	.018	12	view →
LIHC	OS	Median	All	0.149	0.688	.015	9	view →
LUAD	OS	Median	All	0.313	0.812	.015	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GTF2IP4–ACC (DFS)

Open the ACC breakdown →